Scalper1 News
Biotech Isis Pharmaceuticals (ISIS) saw its shares rise Thursday after the company reported positive midstage data on a rare-disease drug candidate. Its development partner Biogen (BIIB) also got a lift. Isis stock was up 3% in midday trading in the stock market today, near 68.50. Earlier, Isis stock rose as high a 71.50, to a nearly three-month high. Biogen stock was up 1.5% in midday trading Thursday. Isis reported on a phase-two trial of Scalper1 News
Scalper1 News